Indication

Growth failure due to Prader-Willi syndrome

Growth failure due to Prader-Willi syndrome is a pediatric endocrine and neurodevelopmental manifestation marked by subnormal linear growth velocity and diminished final adult height. Read more about Growth failure due to Prader-Willi syndrome

7 drugs 3 manufacturers

Advertisement

Drugs that treat it

Common Growth failure due to Prader-Willi syndrome therapies.

Showing 1–7 of 7 drugs

Filter & compare in the drug finder →Opens the drug finder with Growth failure due to Prader-Willi syndrome preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Growth failure due to Prader-Willi syndrome.

Growth failure due to Prader-Willi syndrome is a pediatric endocrine and neurodevelopmental manifestation marked by subnormal linear growth velocity and diminished final adult height.

Occurring in children with Prader-Willi syndrome—a rare genetic condition caused by the loss of paternally expressed genes in the chromosome 15q11–q13 region—this growth deficit is primarily driven by hypothalamic dysfunction leading to impaired growth hormone secretion and low circulating insulin-like growth factor 1 (IGF-1) levels.

Clinically, affected pediatric patients present with marked short stature, delayed bone age, neonatal muscular hypotonia, and altered body composition characterized by reduced lean muscle mass and increased adiposity.

Personalize your experience

Follow Growth failure due to Prader-Willi syndrome and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it